LabGenius
Combining human and machine intelligence to accelerate the discovery of advanced medicines.
- biotechnology
- dt and ls
- core ai
- ai applications
- oncology
- genetics and genomics
- dna
- drug development
- nif defense security and resilience
- ai drug discovery
- proteomics
- techbio
- tech for biotech and pharma
- synthetic biology
- digital pharma
- techbio drug discovery
- nif health crisis preparedness
- compbio
- nif biotech
- bia techbio uk
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | £35.0m | Series B | |
| Total Funding | 000k | ||
| GBP | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | 592 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (3354 %) | (3837 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (3064 %) | (3667 %) | (514 %) |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
LabGenius is a pioneering startup in the drug discovery sector, leveraging advanced technologies like machine learning (ML), synthetic biology, and laboratory automation to develop next-generation protein therapeutics. The company operates in the biopharmaceutical market, focusing on creating innovative treatments for various diseases, including inflammatory conditions.
LabGenius primarily serves pharmaceutical companies and biotech firms looking to enhance their drug discovery processes. By integrating ML-driven protein engineering, LabGenius optimizes therapeutic nanobodies—small antibody fragments that can be used to treat diseases. This approach allows for more efficient and targeted drug development, potentially reducing the time and cost associated with bringing new drugs to market.
The business model of LabGenius revolves around collaborations and partnerships with major pharmaceutical companies. For instance, their collaboration with Ablynx, a Sanofi company, showcases their ability to apply their ML-driven platform to real-world drug discovery challenges. These partnerships not only validate LabGenius's technology but also provide a revenue stream through research and development agreements, milestone payments, and potential royalties from successful drug candidates.
LabGenius makes money by offering its cutting-edge platform as a service to pharmaceutical companies. They charge for access to their technology and expertise, and they may also receive payments based on the success of the drugs developed using their platform. This model ensures a steady income while also aligning their success with the success of their clients' drug development efforts.
The company has garnered attention from top venture capitalists (VCs) and industry experts. For example, Michael Treskow, a partner at Eight Roads, highlighted LabGenius as a startup to watch in 2022. This recognition underscores the company's potential and the industry's confidence in its innovative approach to drug discovery.
Keywords: drug discovery, machine learning, synthetic biology, laboratory automation, protein therapeutics, pharmaceutical partnerships, nanobodies, biopharmaceutical market, innovation, VC recognition.